| Literature DB >> 28629987 |
Ting Li1, Libao Liu2, Hongling Wu1, Shaodan Chen3, Qinchang Zhu4, Hao Gao5, Xiongtao Yu6, Yi Wang7, Wenhan Su2, Xinsheng Yao4, Tao Peng8.
Abstract
Early events in herpes simplex virus type 1 (HSV-1) infection reactivate latent human immunodeficiency virus, Epstein-Barr virus, and human papillomavirus in the presence of acyclovir (ACV). The common use of nucleoside analog medications, such as ACV and pencyclovir, has resulted in the emergence of drug-resistant HSV-1 strains in clinical therapy. Therefore, new antiherpetics that can inhibit early events in HSV-1 infection should be developed. An example of this treatment is Houttuynia cordata Thunb. water extract, which can inhibit HSV-1 infection through multiple mechanisms. In this study, the anti-HSV-1 activity of Houttuynoid A, a new type of flavonoid isolated from H. cordata, was investigated. Three different assays confirmed that this compound could exhibit strong in vitro anti-HSV-1 activity. One assay verified that this compound could inhibit HSV-1 multiplication and prevent lesion formation in a HSV-1 infection mouse model. Mechanism analysis revealed that this compound could inactivate HSV-1 infectivity by blocking viral membrane fusion. Moreover, Houttuynoid A exhibited antiviral activities against other alpha herpes viruses, such as HSV-2 and varicella zoster virus (VZV). In conclusion, Houttuynoid A may be a useful antiviral agent for HSV-1.Entities:
Keywords: Antiviral activities; Early events; Herpes simplex virus type 1; Houttuynoid A; Latent viruses
Mesh:
Substances:
Year: 2017 PMID: 28629987 DOI: 10.1016/j.antiviral.2017.06.010
Source DB: PubMed Journal: Antiviral Res ISSN: 0166-3542 Impact factor: 5.970